10,967 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Fieldview Capital Management LLC

Fieldview Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,967 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,864,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Cardinal Capital Management grew its stake in Jazz Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after buying an additional 66 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Jazz Pharmaceuticals by 9.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 81 shares during the last quarter. UMB Bank n.a. grew its stake in Jazz Pharmaceuticals by 12.6% during the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 81 shares during the last quarter. Pinnacle Associates Ltd. grew its stake in Jazz Pharmaceuticals by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after buying an additional 83 shares during the last quarter. Finally, Fairbanks Capital Management Inc. grew its stake in Jazz Pharmaceuticals by 0.4% during the 3rd quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock worth $3,298,000 after buying an additional 94 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.4%

Jazz Pharmaceuticals stock opened at $230.56 on Friday. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $243.32. The stock has a 50 day moving average of $217.61 and a two-hundred day moving average of $188.84. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. The stock has a market capitalization of $14.48 billion, a price-to-earnings ratio of -11,522.24, a PEG ratio of 0.20 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.07 billion during the quarter. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Rick E. Winningham sold 2,741 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director directly owned 9,567 shares in the company, valued at $2,311,100.19. The trade was a 22.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Neena M. Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the sale, the executive vice president owned 51,549 shares in the company, valued at approximately $11,950,604.67. This trade represents a 2.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 11,941 shares of company stock valued at $2,565,339 over the last 90 days. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on JAZZ. Morgan Stanley restated an “overweight” rating and set a $245.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Robert W. Baird set a $252.00 price target on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Truist Financial set a $256.00 price target on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, May 26th. Finally, Wells Fargo & Company increased their price objective on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $246.06.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Negative Sentiment: Jazz Pharmaceuticals said the Phase 3 LAGOON trial for Zepzelca did not meet its primary endpoint of overall survival in second-line small cell lung cancer. Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
• Negative Sentiment: Reuters reported the trial failure could put Zepzelca’s current regulatory status at risk, raising uncertainty around a key oncology asset. Jazz Pharmaceuticals lung cancer drug fails main trial goal
• Negative Sentiment: Industry coverage from multiple outlets reinforced the setback, suggesting investor concern may persist until Jazz clarifies next steps for Zepzelca. Jazz Pharma announces late-stage trial setback for lung cancer therapy
• Negative Sentiment: FiercePharma noted the latest twist in the Zepzelca saga, highlighting the importance of the drug to Jazz’s cancer franchise and the market’s negative reaction to the failure. In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
• Negative Sentiment: Separately, an SEC filing showed EVP Neena M. Patil sold 1,200 shares earlier this week, a small insider sale that may add to cautious sentiment. Jazz Pharmaceuticals PLC EVP Neena M. Patil sold shares
• Neutral Sentiment: Some recent commentary still frames Jazz as a value stock with a “moderate buy” analyst consensus, but this is being overshadowed by the trial disappointment. Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.